Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been given a consensus recommendation of “Hold” by the eight research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $5.54.
A number of equities research analysts have recently commented on ESPR shares. Needham & Company LLC downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. HC Wainwright downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective for the company. in a research report on Friday, May 1st. Citizens Jmp lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Piper Sandler lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Finally, Cantor Fitzgerald lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st.
Read Our Latest Stock Analysis on ESPR
Esperion Therapeutics Stock Performance
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. The company had revenue of $80.10 million for the quarter, compared to analyst estimates of $84.52 million. As a group, research analysts forecast that Esperion Therapeutics will post 0.05 EPS for the current fiscal year.
Institutional Trading of Esperion Therapeutics
A number of hedge funds have recently modified their holdings of ESPR. Sivia Capital Partners LLC purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at $25,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at $29,000. R Squared Ltd purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at $33,000. Kestra Advisory Services LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $35,000. Finally, KFG Wealth Management LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $37,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.
Featured Stories
- Five stocks we like better than Esperion Therapeutics
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
